id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-349210-8t4a5qqo	Ji, Ping	Immunomodulatory Therapeutic Proteins in COVID‐19: Current Clinical Development and Clinical Pharmacology Considerations	2020-08-10		.txt	text/plain	7698	436	40	Immunomodulatory biological therapies are being evaluated in clinical trials for the management of the systemic inflammatory response and pulmonary complications in patients with advanced stages of COVID‐19. A randomized, open-label, controlled trial for the efficacy and safety of adalimumab in patients with elevated TNF-α levels in the critical stages of severe COVID-19 is ongoing in Shanghai, China, with the main outcome of time to clinical improvement. A Phase 2 trial of the efficacy and safety of infliximab was initiated to evaluate whether early institution of TNF-α inhibitor therapy in patients with severe COVID-19 infections could prevent further clinical deterioration and reduce the need for advanced cardiorespiratory support and early mortality at a 5 mg/kg IV single dose. extrinsic factors ( Route of administration: As described before, the immunomodulatory therapeutic proteins currently in clinical trials for the treatment of COVID-19 mostly are directed towards patients with moderate and severe stages of the disease.	./cache/cord-349210-8t4a5qqo.txt	./txt/cord-349210-8t4a5qqo.txt